Cimetidine for recurrent respiratory papillomatosis in pregnancy as an alternative adjuvant treatment.

Sien Hui TanSakina GhauthYew Toong LiewZulkiflee Abu Bakar

Published in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2023)

Cimetidine is generally safe and not known to be associated with any major teratogenic risks during pregnancy. RRP is postulated to worsen in pregnant women due to the increase in oestrogen levels during pregnancy. Hence, adjuvant therapy was imperative for our patient to reduce recurrent papillomata formation during her pregnancy. Larger scale studies are warranted to assess the use of long-term high-dose cimetidine in terms of efficacy and safety in pregnancy.

Keyphrases

pregnancy outcomes
pregnant women
high dose
preterm birth
early stage
low dose
case report
stem cell transplantation
risk assessment
combination therapy
smoking cessation